I am Legend (@IamLegendfdrg) profile picture

I am Legend

@IamLegendfdrg
Joined August 2026
  • Tweets272
  • Following32
  • Followers16
5Media
Photo by I am Legend (@IamLegendfdrg)Photo by I am Legend (@IamLegendfdrg)Photo by I am Legend (@IamLegendfdrg)Photo by I am Legend (@IamLegendfdrg)Photo by I am Legend (@IamLegendfdrg)
$MRNA theory time. I think moderna is part of two trades the past 2 yrs 1) long biotech basket short moderna (and other short targets) 2) long semicon short biotech basket (bigger part of basket) now that both are unwinding (semicons down) the short baskets also unwinding.
9
let's replace jensen with a white guy im sure he will do better and will never be compromised $NVDA /s
The New York Times (@nytimes) profile pictureThe New York Times
@nytimes12h
Breaking News: A Chinese businesswoman who had a close relationship with Nvidia’s CEO, Jensen Huang, was found to be passing intelligence to Beijing. nyti.ms/3Ukob1t
Nvidia Chief, Jensen Huang, Is Seen as Target of Chinese Spy Plot

Nvidia Chief, Jensen Huang, Is Seen as Target of Chinese Spy Plot

A Chinese businesswoman who had a close relationship with Jensen Huang was found to be passing intelligence to Beijing. President Trump was briefed and took no action.

nytimes.com
41
joke's on the China, jensen cannot be compromised. he either has too many concubines at this point and there's nothing you can leverage against him or he's just too clean
The New York Times (@nytimes) profile pictureThe New York Times
@nytimes12h
Breaking News: A Chinese businesswoman who had a close relationship with Nvidia’s CEO, Jensen Huang, was found to be passing intelligence to Beijing. nyti.ms/3Ukob1t
Nvidia Chief, Jensen Huang, Is Seen as Target of Chinese Spy Plot

Nvidia Chief, Jensen Huang, Is Seen as Target of Chinese Spy Plot

A Chinese businesswoman who had a close relationship with Jensen Huang was found to be passing intelligence to Beijing. President Trump was briefed and took no action.

nytimes.com
19
Antivaxx posts from $mrna shorts in 3.. 2.. 1.. HAHAHAHAHA $MRNA $220 now @seedy19tron @greaterfoolrep @DoodadDoctor
I am Legend (@IamLegendfdrg) profile pictureI am Legend@IamLegendfdrgOct 23
Maybe this guy who is an $mrna short will be an antivaxx quite soon when moderna is back to $220s. it will be the greatest comedy of all time to see a legion of $MRNA shorts turn antivaxx as Moderna moves higher (assuming it goes higher)
1
323
Anthropic should acquire $MRNA for $300B
1
141
$ANT $Meta And correct me if im wrong abt the anthropic founders/co founders not having an asian if im wrong. that's just based on some AI slop content i consumed in social media 3/2
55
AI is dominated by chinese PHDs they outnumber everyone else by like 100 is to 1 (exaggerated). why was there not even 1 of them that "ascended" to have a seat at the top?? $ANT $META 2/2
44
legit question: why does $ANT ipo not have even a single asian founder despite the fact that $META has a whole army of asian AI researchers and anthropic having an army of asian researchers? pretty sure lots of the asian staff worth 100Ms after IPO but still.. 1/2
1
55
I am Legend retweeted
Bloomberg TV (@BloombergTV) profile picture
Bloomberg TV
@BloombergTVOct 26
Moderna CEO Stéphane Bancel calls the company’s cancer vaccine study with Merck a “landmark,” pointing to a 42% improvement compared with Keytruda alone. Bancel says Moderna is now focused on filing the drug with the FDA and believes it could be approved next year bloom.bg/4zasxXT
2
6
2
24
5,521
I spoke with Moderna $MRNA CEO Stéphane Bancel about intismeran and what's next for the cancer vaccine and the biotech he runs. "We know the clinical impact in the Phase 3 study is real and big, so we need to go and be aggressive. We need to explore the biology. There will be some risk, because it’s not going to work everywhere." Read the Q&A: statnews.com/2026/10/26/mode… #ESMO26
Moderna CEO on what’s next after success in cancer vaccine

Moderna CEO on what’s next after success in cancer vaccine

Moderna's CEO Stéphane Bancel on what's next after the recent success in cancer vaccine, and how that impacts the company's business strategy.

statnews.com
25
11
3
81
31,726
I am Legend retweeted
Peter (@gd_pete) profile picture
Peter@gd_peteOct 25
Blown away by the lazy misinformation on $MRNA right now. People are screaming about deaths and missing OS data while ignoring what’s written right on the slide. You can't blame a vaccine for side effects that happened while patients were only on Keytruda pre-vaccine.
1
1
7
1,190
🆕 INTerpath-001 found Intismeran plus pembrolizumab reduced the risk for recurrence or death by 42% and the risk for distant metastasis or death by 38% Presented by @ProfGLongMIA of @Sydney_Uni at @myESMO Congress 2026! #ESMO26 #Melanoma See the data: bit.ly/3VSFuHr
1
3
234
INTerpath-001 is the first-ever positive late-stage study for a personalized cancer vaccine. What comes next? I spoke with experts at this year's #ESMO26 conference: endpoints.news/esmo26-merck-…
Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work begins

Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work begins

Merck and Moderna’s intismeran cut melanoma recurrence risk 42% at ESMO; experts weigh other tumors, manufacturing and boosters.

endpoints.news
1
2
3
181
I am Legend retweeted
Mediamedic (@Mediamediczeex) profile picture
Mediamedic@MediamediczeexOct 24
Personalized mRNA Vaccine Plus Pembrolizumab Reduces Recurrence and Metastasis in Melanoma mediamedic.co/personalized-m… linkedin.com/pulse/personali… #ESMO2026 #GeorginaLong #Melanoma
Image from Mediamedic (@Mediamediczeex)
3
1
20
$MRNA Thanks Adam for the coverage. Thanks for including the patients.
Image from twotreesinthecenter (@twotreesthere)
Adam Feuerstein ✡️ (@adamfeuerstein) profile pictureAdam Feuerstein ✡️
@adamfeuersteinOct 25
After Moderna $MRNA cancer vaccine’s first success, the race is on to expand the impact statnews.com/2026/10/25/mrna… via @DrewQJoseph #ESMO26
After a cancer vaccine’s first success, the race is on to expand the impact

After a cancer vaccine’s first success, the race is on to expand the impact

After 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.

statnews.com
2
15
2,276
After a cancer vaccine’s first success, the race is on to expand the impact statnews.com/2026/10/25/mrna…
After a cancer vaccine’s first success, the race is on to expand the impact

After a cancer vaccine’s first success, the race is on to expand the impact

After 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.

statnews.com
4
16
1
61
7,800
It was a great honour to present the results of the phase 3 INTerpath-001 clinical trial at the #ESMO26 Congress in Madrid. This international trial included 1137 patients, across 157 sites, whose melanoma had been surgically removed, but who were at very high risk of it returning. The trial showed adding #intismeran autogene, an mRNA based individualised neoantigen therapy, to pembrolizumab reduced the risk of recurrence or death by 42%. This is the first phase 3 study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumour can reduce the risk of recurrence or death from cancer. That fingerprint is read by sequencing the tumour, then a ‘wanted poster’ of the cancer is made as mRNA, showing the immune system exactly what to look for and attack. Having succeeded in melanoma, this proof of concept could mark the beginning of a foundational shift in how we treat cancer. Read more >melanoma.org.au/news/persona… A huge thank you to all patients and teams involved. @myESMO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear
Image from Professor Georgina Long AO (Bluesky @gvlongphdmd) (@ProfGLongMIA)
Image from Professor Georgina Long AO (Bluesky @gvlongphdmd) (@ProfGLongMIA)
22
89
10
449
22,083
🧬 Personalized mRNA vaccines work‼️ 📈 INTERPATH-001 met its primary endpoint in resected melanoma patients, paving the way to other tumor types and combinations, including lung 🫁 #cancer 🚀 🌓 One small step for a vaccine, one giant leap for personalized medicine. #ESMO26 @myesmo
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
6
10
630
I am Legend retweeted
Dr. Amy C. Moore (@acmoorephd) profile picture
Dr. Amy C. Moore@acmoorephdOct 24
The era of bespoke mRNA cancer vaccines has arrived #ESMO26
Image from Dr. Amy C. Moore (@acmoorephd)
Image from Dr. Amy C. Moore (@acmoorephd)
Image from Dr. Amy C. Moore (@acmoorephd)
Image from Dr. Amy C. Moore (@acmoorephd)
1
4
10
602
I am Legend retweeted
Yüksel Ürün (@DrYukselUrun) profile picture
Yüksel Ürün
@DrYukselUrunOct 24
A milestone for personalized cancer vaccines. INTErpath-001: 42% lower recurrence/death risk; 24-month RFS 82.2% vs 70%. Can we extend this benefit to other cancers? @myESMO @OncoAlert @OpenMedicineHQ #ESMO26
Image from Yüksel Ürün (@DrYukselUrun)
1
11
25
1,119
Load more